Progressive Supranuclear palsy (PSP) disease progression, management, and healthcare resource utilization: a retrospective observational study in the US and Canada.

Autor: Nysetvold E; AllStripes Research, San Francisco, California, USA., Lopez LN; AllStripes Research, San Francisco, California, USA., Cogell AN; AllStripes Research, San Francisco, California, USA. Ashley.cogell@gmail.com., Fryk H; UCB Pharma, Brussels, Belgium., Pace ND; AllStripes Research, San Francisco, California, USA., Taylor SS; AllStripes Research, San Francisco, California, USA., Rhoden J; AllStripes Research, San Francisco, California, USA.; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Nichols CA; AllStripes Research, San Francisco, California, USA., Pillas D; UCB Pharma, Brussels, Belgium., Klein A; UCB Pharma, Brussels, Belgium., Gasalla T; UCB Pharma, Brussels, Belgium., Scowcroft A; UCB Pharma, Brussels, Belgium.
Jazyk: angličtina
Zdroj: Orphanet journal of rare diseases [Orphanet J Rare Dis] 2024 May 23; Vol. 19 (1), pp. 215. Date of Electronic Publication: 2024 May 23.
DOI: 10.1186/s13023-024-03168-z
Abstrakt: Background: Progressive supranuclear palsy (PSP) is a rare neurodegenerative brain disease with rapid progression and currently limited treatment options. A comprehensive understanding of disease progression, management, and healthcare resource utilization is limited, and further research is challenging due to the small population of patients. To address these challenges in conducting PSP research, individuals with PSP were recruited using a multichannel approach tailored specifically to the PSP community. We performed a retrospective observational study using data abstracted from participant medical records collected from multiple patient care centers.
Results: Seventy-two individuals with PSP were eligible for inclusion. On average, 144 medical documents per participant were collected from an average of 2.9 healthcare centers per participant, with a mean study period of 7.9 years. Among participants with a date of symptom onset documented in the medical records, the median time for the onset of the first fall was 2.0 years (IQR 3.2) before diagnosis, the median onset of unsteady gait or gait impairment was 1.2 years (IQR 1.8) before diagnosis, and the median onset of mobility problems was 0.8 years (IQR 1.8) before diagnosis. The most widely utilized healthcare resources, with at least 85% of participants using each of these resources at some point during the disease course, were medications (100%), imaging (99%), assistive devices (90%), supportive care (86%), and surgeries and procedures (85%).
Conclusions: This retrospective study adds to the current understanding of PSP symptoms, comorbidities, and healthcare resource utilization (HRU) across the disease journey. By involving individuals with PSP and their caregivers or legally authorized representatives in the research process, this study was unique in its approach to participant recruitment and enabled individuals to participate in research without the need for travel. We collected medical documents from multiple healthcare centers, allowing for broad data collection covering the entire disease journey. This approach to the collection of real-world data may be used to generate valuable insights into many aspects of disease progression and management in PSP and many other rare diseases.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje